Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk

Molecular Diagnosis & Therapy
Dominic MitchellJacques LeLorier

Abstract

We recently conducted two economic evaluations of a hypothetical pharmacogenomic test for statin-induced myopathy (SIM) in patients at high cardiovascular risk. Although the models differed in modeling technique and data inputs, both yielded similar results. We believe our approach to assessing the economic value of a diagnostic test was highly advantageous as it characterized the complete range of false-negative and false-positive test outcomes. We used a broad interpretation of test parameters that reflected physician and patient behavioral responses to the test results and accounted for patient adherence to treatment. Both economic evaluations indicated that a highly accurate pharmacogenomic test for SIM would provide a positive incremental net monetary benefit (INMB) for a provincial payer in Canada. However, the value of the test would depend on its ability to accurately diagnose patients when they experience musculoskeletal pain symptoms and guide patients with a test result indicating no SIM to adhere to treatment. Interestingly, our results indicated that a highly inaccurate test would still yield a positive INMB. We found this surprising result was driven by the imbalance of the risk of cardiovascular events outweighin...Continue Reading

References

Jul 27, 2002·Journal of the American College of Cardiology·Richard C PasternakUNKNOWN National Heart, Lung and Blood Institute
Nov 9, 2004·Atherosclerosis. Supplements·T R PedersenUNKNOWN Scandinavian Simvastatin Survival Study Group
Jun 23, 2005·Medical Care·Patrick W SullivanVahram Ghushchyan
Dec 1, 2005·Kidney International·Irina GorodetskayaGlenn M Chertow
Feb 9, 2006·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·V S Catalan, J LeLorier
Jul 25, 2008·The New England Journal of Medicine·UNKNOWN SEARCH Collaborative GroupR Collins
Dec 24, 2008·Pharmacogenomics·Robert S EpsteinBenjamin Zelman
May 12, 2009·The American Journal of Cardiology·José G Díez, Marc Cohen
Oct 17, 2009·Journal of the American College of Cardiology·Deepak VooraGeoffrey S Ginsburg
Aug 7, 2010·Physical Therapy·Stephanie L Di StasiStuart A Binder-Macleod
Feb 24, 2011·Expert Opinion on Drug Safety·Thura T Abd, Terry A Jacobson
May 17, 2011·European Journal of Internal Medicine·R John Irwin, Timothy C Irwin
Jun 4, 2011·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Elena B ElkinKathryn A Phillips
Aug 5, 2011·International Journal of Cardiology·Loukianos S RallidisMaria Anastasiou-Nana
Oct 11, 2011·Journal of the American College of Cardiology·Bob J H van KempenM G Myriam Hunink
Mar 21, 2012·Molecular Oncology·Rahber TharianiScott Ramsey
May 24, 2012·Clinical Pharmacology and Therapeutics·R A WilkeUNKNOWN Clinical Pharmacogenomics Implementation Consortium (CPIC)
Sep 25, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·J Jaime CaroUNKNOWN ISPOR-SMDM Modeling Good Research Practices Task Force
Sep 25, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Uwe SiebertUNKNOWN ISPOR-SMDM Modeling Good Research Practices Task Force
Sep 25, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Jonathan KarnonUNKNOWN ISPOR-SMDM Modeling Good Research Practices Task Force
Dec 12, 2012·Current Atherosclerosis Reports·Patricia ManingatJan L Breslow
Mar 19, 2013·Journal of the American College of Cardiology·Kevin F EricksonJeremy D Goldhaber-Fiebert
May 21, 2013·Stroke; a Journal of Cerebral Circulation·Sara B JonesWayne D Rosamond
Aug 21, 2013·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Mike PauldenMurray Krahn
Sep 11, 2013·American Heart Journal·Warner M MampuyaLeslie Cho
Sep 27, 2013·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Lieven AnnemansKatherine Payne
Nov 2, 2013·Neuromuscular Disorders : NMD·M Needham, F L Mastaglia
Jan 25, 2014·PLoS Currents·Alison Stewart
Apr 12, 2014·Clinical Pharmacology and Therapeutics·S E Gryn, R A Hegele
Jun 24, 2014·American Heart Journal·Harsha V GangaPaul D Thompson
Feb 20, 2015·European Heart Journal·Erik S StroesUNKNOWN European Atherosclerosis Society Consensus Panel
Mar 17, 2015·The New England Journal of Medicine·Jennifer G RobinsonUNKNOWN ODYSSEY LONG TERM Investigators
Mar 17, 2015·The New England Journal of Medicine·Marc S SabatineUNKNOWN Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators
Mar 31, 2015·Atherosclerosis·Jaideep PatelLisa Christopher-Stine
Apr 1, 2015·Circulation·David H FitchettSubodh Verma
Nov 18, 2015·Deutsches Ärzteblatt International·Ulrich LaufsWinfried März
Jun 3, 2016·Expert Opinion on Pharmacotherapy·Jaideep PatelMaciej Banach

❮ Previous
Next ❯

Citations

Apr 3, 2020·Expert Opinion on Drug Safety·Dragana NikolicManfredi Rizzo

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Software Mentioned

SIM

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.